- Home
- KTB vs APLS Comparison
KTB vs APLS Comparison
Compare KTB & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTB
- APLS
- Stock Information
- Founded
- KTB 2018
- APLS 2009
- Country
- KTB United States
- APLS United States
- Employees
- KTB N/A
- APLS N/A
- Industry
- KTB Apparel
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- KTB Consumer Discretionary
- APLS Health Care
- Exchange
- KTB Nasdaq
- APLS Nasdaq
- Market Cap
- KTB 3.6B
- APLS 3.5B
- IPO Year
- KTB N/A
- APLS 2017
- Fundamental
- Price
- KTB $77.39
- APLS $27.97
- Analyst Decision
- KTB Strong Buy
- APLS Buy
- Analyst Count
- KTB 6
- APLS 20
- Target Price
- KTB $89.67
- APLS $34.11
- AVG Volume (30 Days)
- KTB 935.6K
- APLS 3.0M
- Earning Date
- KTB 08-07-2025
- APLS 07-31-2025
- Dividend Yield
- KTB 2.68%
- APLS N/A
- EPS Growth
- KTB 5.71
- APLS N/A
- EPS
- KTB 4.47
- APLS N/A
- Revenue
- KTB $2,650,638,000.00
- APLS $754,649,000.00
- Revenue This Year
- KTB $20.34
- APLS $10.84
- Revenue Next Year
- KTB $11.09
- APLS $10.51
- P/E Ratio
- KTB $17.33
- APLS N/A
- Revenue Growth
- KTB 3.44
- APLS 20.02
- 52 Week Low
- KTB $50.00
- APLS $16.10
- 52 Week High
- KTB $96.80
- APLS $41.94
- Technical
- Relative Strength Index (RSI)
- KTB 73.54
- APLS 74.59
- Support Level
- KTB $70.75
- APLS $26.23
- Resistance Level
- KTB $73.53
- APLS $28.87
- Average True Range (ATR)
- KTB 2.33
- APLS 1.07
- MACD
- KTB 1.33
- APLS 0.18
- Stochastic Oscillator
- KTB 99.05
- APLS 84.04
About KTB Kontoor Brands Inc.
Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.